Pharmaceutical Diversion Education Inc.

  • Home
  • About Us
    • Scope of the Problem
    • About John Burke
    • About Kim New
  • Expert Witness
  • Health Care Consulting
  • Presentations
    • Drug Diversion vs. Pain Management – Training
    • Healthcare Facility Diversion Training
    • Rx Drug Abuse – Scope of the Problem
  • Resources
    • News/Aritcles
    • Videos
    • Links
  • Contact Us

Drug Diversion and Abuse: Rescheduling of Hydrocodone

January 16, 2014 by John Burke

A situation that has been debated over and over again finally seems to be becoming a reality for those who have wanted hydrocodone combination products put into CII status. It seems that the FDA recently cleared the way for this to happen, a move the Drug Enforcement Administration has endorsed for some time.

Of course, pure hydrocodone has always been a CII product, but it is found only in compounding pharmacies. That’s about to change, too, as Zogenix Pharmaceuticals obtained approval for an extended-release hydrocodone pain reliever called Zohydro. Understandably, it was placed into the CII category since it has no acetaminophen or ibuprofen combination.

When you take a look at what makes a prescription drug a CII, the most restrictive prescription schedule, it is the propensity for addiction and abuse. A CII drug is at the top of the food chain, and purely by that definition, hydrocodone combinations clearly fit the bill. Hydrocodone has long been the most abused pharmaceutical, representing half or more of the caseload for those who work in the law enforcement field combating drug diversion.

Many would argue that with hydrocodone combinations being in the CIII category, fake call-ins and refill alteraions are possible, unlike with their CII cousins. The combinations are bunched together with the CIV and CV pharmaceuticals, unlike the CII drugs, which have the distinction of being in their own files. Criminal penalties with CIII drugs are typically less in state courts and require a tractor trailer load to generate any interest by US attorneys in federal court!

Ohio, for example, requires a person to possess at least 30 extra-strength hydrocodone combination pills illegally to generate a low-level felony charge while it stays a CIII. Once the schedule changes, possession of just 1 of these same pills becomes a felony, with more stringent felony charges for a larger number of doses. Other states will be looking at similar changes in charging suspects with the illegal possession of hydrocodone combination products.

Another aspect to look at in this debate is the fact that hydrocodone is also the #1 prescribed prescription drug in the United States. With these overwhelming numbers in mind, a certain percentage of controlled substances will be abused, and with hydrocodone’s numbers, a fair amount is bound to be headed for abuse in our society.

Although many want hydrocodone combination products to be CII because it takes away the ability to call them in to the pharmacy and give patients refills, this is the very reason some prescribers and patients want hydrocodone to remain a CIII. The biggest argument is that legitimate patients will have to visit their prescriber each time they want a refill or request a call-in, adding the inconvenience and expense of additional office visits to the already rising costs of health care.

However, some pain management experts stress that prescribing hydrocodone combination products long term is likely not a sound treatment for those with chronic or cancer pain who need pain relief opiates for extended periods of time—or the rest of their lives. Many experts will recommend an extended-release product void of acetaminophen and other combination drugs for these types of patients. In addition, once they are a CII, combination products could be prescribed for up to 90 days at 1 visit, as long as all of the prescriptions are dated the day of issuance with the indication of “do not fill until” on the script.

Of course, it is likely that the other contingency not excited about hydrocodone combination products becoming a CII is the dozens of generic companies that manufacture the drug. By placing this drug in CII, it will likely result in a reduction in the prescribing of hydrocodone combination pharmaceuticals. It can definitely be argued that making this drug a CII seriously impacts the prescriber’s ability to have an optional pain reliever for patients when the prescriber feels that a CII drug is not necessary or appropriate.

Years ago, the state of Florida made hydrocodone combination pharmaceuticals a CII, but that ended up being rescinded almost immediately after incredible pressure. In this case, once it is placed into this elite category of abuse and addiction, it will almost surely never return to the CIII status it enjoys today.

I am very interested to know how our nation’s pharmacists view this potential change. Is it a good idea that is a long time in coming, or do you think it negatively impacts patients?

Filed Under: Drug Diversion, Pain Management, Pharmacy Times Article Tagged With: Hydrocodone, Zogenix

News Topics

  • Abuse Prevention (68)
  • Drug Diversion (118)
  • Health Care Facilities (44)
  • Pain Management (40)
  • PDE News (3)
  • Pharmacies (25)
  • Pharmacy Times Article (70)
  • Uncategorized (1)

How BIG is the problem?

Year after year, state and local law enforcement statistics indicate that pharmaceuticals are almost 30% of the overall drug problem in the United States, running a close second only marijuana abuse. However, until recently, law enforcement, health care professionals, and the general public have placed little emphasis on this huge problem.

Let PDE provide you with the most up to date information and best practices for protecting your organization.

Signup for Newsletter!

unsubscribe from list

About PDE

Pharmaceutical Diversion Education (PDE) is designed to assist a wide range of the population in understanding the potential abuse and addiction that can be associated with prescription medication.

Drug Diversion:
Any Criminal Act Involving a Prescription Drug.

PDE Recent Articles

  • Pain Politics Podcast
  • A Good Start: President Trump and the Opioid Abuse Crisis
  • Finding Balance Amid the Opioid Abuse Crisis
  • Who Is to Blame for the Opioid Crisis?
  • The War on Drug Abuse A 3-Pronged Approach
  • Filling Prescriptions Under False Names

Areas of Discussion

  • Abuse Prevention (68)
  • Drug Diversion (118)
  • Health Care Facilities (44)
  • Pain Management (40)
  • PDE News (3)
  • Pharmacies (25)
  • Pharmacy Times Article (70)
  • Uncategorized (1)

Hot Topics

Abuse Deterrent Formulation Counterfeit Doctor Shopping FDA Fentanyl Guard Your Meds Heroin Hydrocodone Marijuana Naloxone Overdose Oxycodone OxyContin Pharmacist Prescription Drug Drop Boxes Prescription Monitoring Programs Prescription Take Back Steroids Training Veterinarian Vivitrol Zogenix Zohydro

Return to top of page

Hosting & Design by Comprehensive IT Solutions

Copyright © 2021 · Log in